Relevance of the Anti-Inflammatory Properties of Curcumin in Neurodegenerative Diseases and Depression
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
This review is an attempt to summarize our current understanding of curcumin’s potential as a neuroprotectant and an antidepressant. This dual property confers a unique advantage to this herbal medication, believed to be devoid of any major side effects, to combat commonly observed co-morbid conditions of a neurodegenerative and a neuropsychiatric disorder. Moreover, in line with the theme of this series, the role of inflammation and stress in these diseases and possible anti-inflammatory effects of curcumin, as well as its interaction with signal transduction proteins as a common denominator in its varied mechanisms of action, are also discussed. Thus, following a brief introduction of curcumin’s pharmacology, we present research suggesting how its anti-inflammatory properties have therapeutic potential in treating a devastating neurological disorder (Parkinson’s disease = PD) and a debilitating neuropsychiatric disorder (major depressive disorder = MDD). It is concluded that curcumin, or better yet, an analog with better and longer bioavailability could be of important therapeutic potential in PD and/or major depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 2×
“In this regard, it has been suggested that addition of piperine could enhance its absorption [116,129].”
BackgroundA Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“including PD as well as MDD [65–68].”
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“, hippocampus and olfactory system: [41–43]).”
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · cited 2×
“, IL-6 and IL-1β) can induce symptoms of a syndrome termed “sickness behavior” [89,92,93], which include”
BackgroundSteptoe, A., Hamer, M., & Chida, Y. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.03.011 · Cited by 1,278
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress
Koo, J. W., & Duman, R. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708092105 · Cited by 862 · cited 1×
“The mechanism of cytokine actions include impairment of neurogenesis and exacerbation of neuronal death [69–73] and may involve disruption of survival signaling pathways and caspase-dependent cascades, as well as alteration of normal receptor”
BackgroundHurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811 · cited 1×
“For example, IL-6 may not only have a pro-inflammatory action [61,62], but may also act to attenuate or down-regulate synthesis of other pro-inflammatory cytokines (e.”
BackgroundMaes, M., Song, C., Lin, A., De Jongh, R., Van Gastel, A., Kenis, G., Bosmans, E., De Meester, I., Benoy, I., Neels, H., et al. (1998) · Cytokine · doi:10.1006/cyto.1997.0290 · Cited by 772 · cited 2×
“Stress is known to alter immune functioning [98].”
BackgroundGoshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T., & Yirmiya, R. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002055 · Cited by 762 · cited 2×
“Animal studies have also demonstrated that stressors increase cytokine levels such as IL-1beta and IL-6 in the blood and in various regions of the brain [49,69,101,102].”
BackgroundNeuronal plasticity and survival in mood disorders
Duman, R. S., Malberg, J., Nakagawa, S., & D’Sa, C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00935-5 · Cited by 652
Cytokines and psychopathology: Lessons from interferon-α
Capuron, L., & Miller, A. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.009 · Cited by 562 · cited 1×
“administration of high levels of pro-inflammatory cytokines can cause changes in behavior similar to depression and that attenuation of inflammatory response reduces depressive symptoms [96,97].”
BackgroundA Guide to Neurotoxic Animal Models of Parkinson's Disease
Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483
Banasr, M., Chowdhury, G. M. I., Terwilliger, R., Newton, S. S., Duman, R. S., Behar, K. L., & Sanacora, G. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.106 · Cited by 458
REVIEW: Curcumin and Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450 · cited 1×
“A survey of clinical studies on potential usefulness of curcumin in Alzheimer’s disease [124,125]; dementia [126] and PD further support its potential therapeutic benefits [127,128].”
BackgroundWolkowitz, O. M., Mellon, S. H., Epel, E. S., Lin, J., Dhabhar, F. S., Su, Y., Reus, V. I., Rosser, R., Burke, H. M., Kupferman, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017837 · Cited by 421 · cited 1×
“pathway [36–40], particularly in areas implicated in the pathophysiology of depression (e.”
BackgroundInterleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression?
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.8.1189 · Cited by 364
Khairova, R. A., Machado-Vieira, R., Du, J., & Manji, H. K. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709009924 · Cited by 350
Inflammation, Depression and Dementia: Are they Connected?
Leonard, B. E. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9385-y · Cited by 342
Hayley, S., Poulter, M. O., Merali, Z., & Anisman, H. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.051 · Cited by 324
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324
Depressive-like behavior induced by tumor necrosis factor-α in mice
Kaster, M. P., Gadotti, V. M., Calixto, J. B., Santos, A. R. S., & Rodrigues, A. L. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.018 · Cited by 294 · cited 1×
“Recently, it has been shown that direct administration of TNF-α can also induce a depressive-like state that can be blocked with the anti-TNF-α antibody [103].”
BackgroundIL-6: Insights into Novel Biological Activities
Barton, B. E. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4420 · Cited by 269 · cited 8×
“Inhibition of TNF [59] may contribute to a physical interaction with other key signaling protein like BDNF that might enhance its antidepressant effect.”
BackgroundInfluentialWang, C., Zhang, X., Teng, Z., Zhang, T., & Li, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.051 · Cited by 233
Stress, depression and Parkinson's disease
Hemmerle, A. M., Herman, J. P., & Seroogy, K. B. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.035 · Cited by 225 · cited 1×
“Moreover, neurological diseases like Alzheimer’s disease [50,105], amyotrophic lateral sclerosis, epilepsy, Huntington’s disease, multiple sclerosis, and PD [106] are often co-morbid with depression and express inflammatory markers.”
BackgroundCurcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study
Lopresti, A. L., Maes, M., Maker, G. L., Hood, S. D., & Drummond, P. D. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.001 · Cited by 216 · cited 1×
“These studies include randomized controlled trials of curcumin alone [114,115], or with piperine, an alkaloid found in black and long peppers, to boost the bioavailability of curcumin [116].”
BackgroundPollak, Y., & Yirmiya, R. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003152 · Cited by 215
Sandhir, R., Yadav, A., Mehrotra, A., Sunkaria, A., Singh, A., & Sharma, S. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8261-y · Cited by 204
Cell atrophy and loss in depression: reversal by antidepressant treatment
Banasr, M., Dwyer, J. M., & Duman, R. S. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.002 · Cited by 201
O'Sullivan, J. B., Ryan, K. M., Curtin, N. M., Harkin, A., & Connor, T. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570800967x · Cited by 146 · cited 1×
“Furthermore, research suggests that neuroinflammation is suppressed by norepinephrine (NE), and that NE uptake inhibitors’ therapeutic efficacy in depression may be at least partially related to this mechanism [51].”
BackgroundWang, Y., Yin, H., Li, J., Zhang, Y., Han, B., Zeng, Z., Qiao, N., Cui, X., Lou, J., & Li, J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.10.024 · Cited by 36 · cited 1×
“For example, research shows its protection against: chronic inflammation associated with Alzheimer’s disease [117]; axonal degeneration from local neuroinflammation [118]; β-amyloid induced degeneration [119]; peripheral neuropathy [120]; experimental models of Huntington’s disease [121]; okadaic acid induced memory i…”
Background
Cited by
Zhang, J., Zheng, Y., Luo, Y., Du, Y., Zhang, X., & Fu, J. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.09.020 · Cited by 464
Formulations of Curcumin Nanoparticles for Brain Diseases
Del Prado-Audelo, M. L., Caballero-Florán, I. H., Meza-Toledo, J. A., Mendoza-Muñoz, N., González-Torres, M., Florán, B., Cortés, H., & Leyva-Gómez, G. (2019) · Biomolecules · doi:10.3390/biom9020056 · Cited by 191
“It has been demonstrated that curcumin reduces the expression of several inflammatory cytokines, including IL-1α, IL-1β, IL-6, TNF, IFNγ, and many others (Figure 8) [42,43].”
BackgroundXu, M.-X., Yu, R., Shao, L.-F., Zhang, Y.-X., Ge, C.-X., Liu, X.-M., Wu, W.-Y., Li, J.-M., & Kong, L.-D. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.01.001 · Cited by 61
Metadata
- Authors
- Tizabi, Y., Hurley, L., Qualls, Z., & Akinfiresoye, L.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2014-12-12
- Volume
- 19
- Issue
- 12
- Pages
- 20864-20879
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2021934889
- Cited by
- 81
- References
- 35
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.